Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1068-1074

  Kudoh, Shinzoh ^a   Fujiwara, Yasuhiro ^a   Takada, Yoshiki ^a   Yamamoto, Hidehiko ^a   Kinoshita, Akitoshi ^a   Ariyoshi, Yutaka ^a   Furuse, Kiyoyuki ^a   Fukuoka, Masahiro ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031887545     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1068     Document Type: Article

References (38)

1. Aisner J, Alberto P, Comis RL, et al: Role of chemotherapy in small-cell lung cancer: A consensus report of the International Association for the Study of Lung Cancer Workshop. Cancer Treat Rep 67:37-43, 1983
2. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
3. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
4. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small-cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 107:451-458, 1987
5. Feld R, Evans WK, Coy P, et al: Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 5:1401-1409, 1987
6. Johnson DH, Einhorn LH, Birch R, et al: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731-1738, 1987
7. Ihde DC, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022-2034, 1994
8. Taylor CW, Crowley J, Williamson SK, et al: Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: A Southwest Oncology Group pilot study. J Clin Oncol 8:1811-1817, 1990
9. Murray N, Shah A, Osoba D, et al: Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9:1632-1638, 1991
10. Souhami RL, Rudd R, de Elvira MCR, et al: Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: A Cancer Research Campaign trial. J Clin Oncol 12:1806-1813, 1994
11. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
12. Matsuzaki T, Yokokura T, Mutai M, et al: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308-312, 1988
13. Hsiang YH, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
14. Andoh T, Ishii K, Suzuki Y, et al: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565-5569, 1987
15. Negoro S, Fukuoka M, Niitani H, et al: Phase II study of CPT-11, new camptothecin derivative, in small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 10:241, 1991 (abstr 822)
16. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
17. Takada M, Fukuoka M, Kudoh S, et al: Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice. Proc Am Assoc Cancer Res 33:226, 1992 (abstr 1351)
18. Kudoh S, Takada M, Masuda N, et al: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against lung tumor xenografts. Jpn J Cancer Res 84:203-207, 1993
19. Masuda N, Fukuoka M, Kudoh S, et al: Phase 1 and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777-782, 1993
20. Masuda N, Fukuoka M, Kudoh S, et al: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 12:90-96, 1994
21. Nakagawa K, Fukuoka M, Niitani H, et al: Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 12:332, 1993 (abstr 1104)
22. Masuda N, Fukuoka M, Takada M, et al: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780, 1992
23. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva, Switzerland. World Health Organization, 1979
24. Sierocki JS, Hilaris BS, Hopfan S, et al: Cis-dichlorodiammineplatinum (II) and VP-16-213: An active induction regimen for small-cell carcinoma of the lung. Cancer Treat Rep 63:1593-1597, 1979
25. Evans WK, Shepherd FA, Feld R, et al: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3:1471-1477, 1985
26. Turrisi AT, Glover DJ: Thoracic radiotherapy variables: Influence on local control in small-cell lung cancer limited disease. Int J Radiat Oncol Biol Phys 19:1473-1479, 1990
27. Johnson BE, Salem C, Nesbitt J, et al: Limited stage small-cell lung cancer treated with concurrent hyperfractionated chest radio-therapy and etoposide/cisplatin. Lung Cancer 9:215-265, 1993
28. Johnson DH, Kim K, Sause W, et al: Cisplatin (P) & etoposide + thoracic radiotherapy (TRT) administered once or twice daily (BID) in limited stage (LS) small-cell lung cancer (SCLC): Final report of intergroup trial 0096. Proc Am Soc Clin Oncol 15:374, 1996 (abstr 1113)
29. Takada M, Fukuoka M, Furuse K, et al: Phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (C) and etoposide (E) for limited-stage (LS) small-cell lung cancer (SCLC): Preliminary results of the Japan Clinical Oncology Group (JCOG). Proc Am Soc Clin Oncol 15:372, 1996 (abstr 1103)
30. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11:336-344, 1993
31. Kudoh S, Negoro S, Fukuoka M, et al: A phase I-II study of weekly irinotecan (CPT-11) and simultaneous thoracic radiotherapy (TRT) for unresectable locally advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15:372, 1996 (abstr 1102)
32. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992
33. Schiller JH, Kim K, Johnson DH: Phase II study of topotecan in extensive stage small-cell lung cancer. Proc Am Soc Clin Oncol 13:330, 1994 (abstr 1093)
34. Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995
35. Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small-cell lung cancer. Eur J Cancer 30A:1058-1060, 1994
36. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5:283-285, 1994
37. Jassen J, Karnicka-Mlodkowsha H, van Pottelsberghe C, et al: Phase II study of vinorelbine (navelbine) in previously treated small-cell lung cancer patients. Eur J Cancer 29A: 1720-1722, 1993
38. Kelly K, Wood ME, Bunn PA Jr: A phase I study of cisplatin, etoposide, and paclitaxel (PET) in extensive stage small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 15:400, 1996 (abstr 1214)